Table S3.
Best overall tumor response rate by investigator assessment: full analysis set
| Pasireotide LAR n=53 | Octreotide LAR n=57 | |
|---|---|---|
| Number of patients analyzed | 51 | 52 |
| Tumor response rate, n (%) | ||
| CR | 0 | 0 |
| PR | 1 (2.0) | 1 (1.9) |
| SD | 36 (70.6) | 38 (73.1) |
| PD | 5 (9.8) | 6 (11.5) |
| UNK | 9 (17.6) | 7 (13.5) |
| Response analysis, n (%) | ||
| ORR (CR + PR) [95% CI] | 1 (2.0) [0.0–10.4] | 1 (1.9) [0.0–10.3] |
| OR, 1.02; 95% CI, 0.06–16.76 P=0.99 | ||
| Disease control rate (CR + PR + SD) [95% CI] | 37 (72.5) [58.3–84.1] | 39 (75.0) [61.1–86.0] |
| OR, 0.88; 95% CI, 0.37–2.12 P=0.78 | ||
Abbreviations: CI, confidence interval; CR, complete response; octreotide LAR, octreotide long-acting repeatable; OR, odds ratio; ORR, objective response rate; pasireotide LAR, pasireotide long-acting release; PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.